Upon IND clearance, Phase 2 clinical trial investigating adrulipase as a treatment for exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis is expected to initiate in early 2023 with topline clinical data anticipated in the first half of 2023
https://finance.yahoo.com/news/first-wave-biopharma-files-investigational-120000369.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.